Incyte (INCY) Restructuring Costs (2010 - 2016)
Incyte's (INCY) quarterly Restructuring Costs came in at $1.6 million in Q4 2016, up 6.67% quarter-over-quarter from $1.5 million in Q3 2016.
Analysis
Incyte (INCY) Restructuring Costs (2010 - 2016) Analysis & Trends
Incyte (INCY) has reported Restructuring Costs for 3 consecutive years, with $1.6 million the latest figure, recorded in Q4 2016.
- For the quarter ending Q4 2016, Restructuring Costs changed N/A year-over-year to $1.6 million; the trailing twelve-month figure through Dec 2016 stood at $4.4 million (changed N/A YoY), and the FY2016 full-year result was $1.6 million, changed N/A from the prior year.
- Restructuring Costs advanced to $1.6 million in Q4 2016 per INCY's latest filing, from $1.5 million in the prior quarter.
- Across five years, Restructuring Costs topped out at $1.6 million in Q4 2016 and bottomed at $1.3 million in Q2 2016.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 646.71 Bn | 625.95 Bn | 17.26 Bn |
| 2 | AbbVie | 442.22 Bn | 435.65 Bn | 12.70 Bn |
| 3 | Merck | 366.92 Bn | 359.78 Bn | 12.21 Bn |
| 4 | Novartis Ag | 266.90 Bn | 259.21 Bn | 11.24 Bn |
| 5 | Pfizer | 159.20 Bn | 147.50 Bn | 10.94 Bn |
| 6 | Sanofi | 52.44 Bn | 45.06 Bn | 10.79 Bn |
| 7 | Revolution Medicines | 44.11 Bn | 44.11 Bn | - |
| 8 | Incyte | 25.38 Bn | 20.85 Bn | 1.57 Bn |
| 9 | United Therapeutics | 21.50 Bn | 18.84 Bn | 683.80 Mn |
| 10 | Neurocrine Biosciences | 15.58 Bn | 15.19 Bn | 935.80 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2016 | 1.60 Mn |
| Sep 30, 2016 | 1.50 Mn |
| Jun 30, 2016 | 1.30 Mn |
| Jun 30, 2011 | 20,000.00 |
| Mar 31, 2011 | 691,000.00 |
| Dec 31, 2010 | 20,000.00 |
| Sep 30, 2010 | -139,000.00 |
| Jun 30, 2010 | -145,000.00 |
| Mar 31, 2010 | -115,000.00 |